Frontiers in immunology · 2026
B cell-mediated immune surveillance defines the favorable prognosis of occult breast cancer: a multi-omics study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Junjie, Zhang Rui, Li Ziyan, Li Xiaoqian, Yuan Xuetao, Zhang Jingyi, Chai Na, Zhang Yunpeng, Zhang Huimin
Аннотация
BACKGROUND: Occult breast cancer (OBC) presents with axillary lymph node (ALN) metastases without detectable primary tumor (PT) yet exhibits paradoxically favorable prognosis compared to non-occult breast cancer (non-OBC). We aimed to elucidate mechanisms underlying PT clearance by integrating multi-omics approaches to characterize the unique immune landscape.
METHODS: Survival outcomes were validated using the Surveillance, Epidemiology, and End Results (SEER) database (n=12,162) with propensity score matching (PSM). Molecular features were characterized via quantitative proteomics, while immune landscapes were assessed using bulk transcriptomics. Single-cell RNA sequencing (scRNA-seq) and CellChat analysis dissected cellular heterogeneity and intercellular communication within tumor microenvironment.
RESULTS: Survival analysis confirmed OBC patients have survival comparable to T1N+M0 but significantly better than T2-3N+M0 breast cancer (BC) patients. Proteomic profiling identified B cell-related pathway upregulation in OBC lymph nodes (LN). Transcriptomics revealed enriched B cell infiltration in T1 tumors correlating with improved survival. scRNA-seq further demonstrated that B cells in T1 tumors act as central hubs in intercellular communication. These cells orchestrate a robust anti-tumor response via multi-faceted secretory signals (e.g., tumor necrosis factor, TNF; B-cell activating factor, BAFF) and contact-dependent interactions (e.g., CD40; major histocompatibility complex, MHC), effectively recruiting and activating immune effectors.
CONCLUSION: Our findings suggest that B cell-mediated immune surveillance may be a key mechanism contributing to the clearance of PT in OBC. These exploratory results underscore the potential of B cells as prognostic biomarkers and therapeutic targets in BC, pending functional validation in larger cohorts.
METHODS: Survival outcomes were validated using the Surveillance, Epidemiology, and End Results (SEER) database (n=12,162) with propensity score matching (PSM). Molecular features were characterized via quantitative proteomics, while immune landscapes were assessed using bulk transcriptomics. Single-cell RNA sequencing (scRNA-seq) and CellChat analysis dissected cellular heterogeneity and intercellular communication within tumor microenvironment.
RESULTS: Survival analysis confirmed OBC patients have survival comparable to T1N+M0 but significantly better than T2-3N+M0 breast cancer (BC) patients. Proteomic profiling identified B cell-related pathway upregulation in OBC lymph nodes (LN). Transcriptomics revealed enriched B cell infiltration in T1 tumors correlating with improved survival. scRNA-seq further demonstrated that B cells in T1 tumors act as central hubs in intercellular communication. These cells orchestrate a robust anti-tumor response via multi-faceted secretory signals (e.g., tumor necrosis factor, TNF; B-cell activating factor, BAFF) and contact-dependent interactions (e.g., CD40; major histocompatibility complex, MHC), effectively recruiting and activating immune effectors.
CONCLUSION: Our findings suggest that B cell-mediated immune surveillance may be a key mechanism contributing to the clearance of PT in OBC. These exploratory results underscore the potential of B cells as prognostic biomarkers and therapeutic targets in BC, pending functional validation in larger cohorts.